Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Apellis pharmaceuticals, inc. save search
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Published: 2022-06-07 (Crawled : 12:20) - biospace.com/
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 3.52%
H: 1.44%
C: -2.89%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -1.18%
H: 1.95%
C: 1.75%
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -7.87%
H: 5.53%
C: 5.37%
rare kidney phase 3
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Published: 2022-05-02 (Crawled : 20:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.39%
H: 4.58%
C: -0.87%
phase 3
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Published: 2022-03-16 (Crawled : 11:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.3%
H: 14.33%
C: 10.42%
phase 3
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.98%
H: 0.0%
C: -5.67%
results retina phase 3
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.88%
H: 2.83%
C: 0.94%
fda results phase 3 topline fda ide
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
Published: 2021-03-17 (Crawled : 00:00) - prnewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.09%
H: 3.29%
C: -4.14%
results phase 3
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
Published: 2021-03-17 (Crawled : 22:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.09%
H: 3.29%
C: -4.14%
results phase 3
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
Published: 2020-12-10 (Crawled : 11:01) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.1%
H: 3.46%
C: 0.25%
positive results phase 3 topline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.